profit improv remark may abl
off-set supplement gain potenti nexsi contract
true would materi de-risk debat plasma
dynam worth monitor alarm
profit plasma quarter report revenu
organ slightli better estim
organ impli bp momentum acceler plasma revenu
organ estim amid lower collect volum
growth see expect improv hospit vs
mse rel in-lin blood center vs mse
drove beat reflect revenu pull forward guidanc unchang
across segment reiter organ corpor level margin
continu deliv signific upsid margin beat estim
bp driven mix price product similar see margin
guidanc rais impli
discuss ep beat estim driven margin upsid
vs mse tax vs mse interest vs mse impact
off-set bottom line guidanc rais impli
plasma collect slow meaning plasma growth
modestli estim repres bp momentum
deceler na collect volum mid-singl digit forecast
improv clear deceler
underli caus unclear manag cite declin
number donor improv economi ineffici center and/or
anniversari tough comp causal factor econom factor
challeng comp like ineffici view
plasma price tailwind compani seen past
four quarter anniversari without new contact win result
absolut growth slowdown see major growth
volume-driven
liquid solut less relev debat segment come
pressur higher volum provid rememb
high volum contact player salin rather small spot market
player industri return stabil spot market salin
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
contract impact player wherea baxter
less affect see manag forecast volum declin
busi compani remain disciplin margin
aggress compet price
despit headwind manag remain confid organ
growth model impli momentum stabil
plasma trend concern plasma suppli demand driven industri
given signific lead time open collect center manufactur finish
therapeut product raw plasma build fraction plant
temporari imbal common econom factor also know
impact collect dynam collect fee vari materi cycl
alarm reason
guidanc collect growth consist long-run
ppta notifi fda igg shortag back august
see demand trend
fluctuat address fraction increas center
hour higher donat fee off-set increas price
nexsi document abil increas yield collect strain
potenti incentiv larg player adopt
commentari regard time larg custom contract limit
continu model contract drive plasma growth expect
contract time becom greater focu next quarter
margin look conserv second half deliv
margin rais margin guidanc second consecut
quarter impli bp
lower note break histor trend past three year
margin averag bp higher manag allud
sale forc expans plan hospit segment still see margin guidanc
conserv discret spend highlight margin
flat would impli ep upsid
past three year full-year ep come current
guidanc impli midpoint assum ep
deriv would impli point ep upsid
buy-back activ drive upsid current incorpor
model remaind buy-back activ
share drive increment upsid model margin
ep like prove conserv stori plasma
contract nexsi stori underappreci
potenti core busi profit next great debat whether
complex reduct initi recent announc oper excel
program latter worth save bp
margin off-set supplement benefit larg plasma contract
current outlook
hospit blood center dynam
hospit organ growth impli point momentum
acceler teg continu drive segment growth
compani earli stage teg us trauma launch commentari
suggest encourag date expect continu traction
trauma launch well contribut recent
launch channel platelet cartridg sale forc expans expect
continu focu hospit compani recent enter full
commerci launch safetrac tx drive acceler
manag model segment growth in-lin
guidanc
blood center segment growth aid favor order
time japan expect revers apheresi
busi appear stabil altern provid continu
compet price manag forecast headwind whole blood
persist transfus rate continu declin amplifi price
pressur manag remain commit stabl cash flow
busi divest asset may get harder trend continu
guidanc growth maintain impli point
momentum deceler model segment growth
drive bp corpor
profit inflect continu remain overweight consist see
continu deliv top-line upsid although slightli weaker
plasma number materi inflect profit date margin
grown point y/i still see margin ep guidanc
conserv variou restructur program drive bp
addit leverag beyond time larg custom contract
like come focu later year current includ
plasma estim price target base
ebitda premium smid cap compar given slightli higher organ
growth profil meaning greater margin earn leverag
haemonet nexsi drive transform stori
haemonet nexsi drive transform stori
price target reflect ebitda premium
upsid nexsi price complex reduct initi dropthrough
balanc sheet option drive ebit achiev
per liter increment plasma price nexsi greater cost
save drop balanc sheet option third parti financ
capit deploy drive materi upsid ebit
nexsi cost restructur program drive ebit
haemonet abl achiev favor increment plasma price
nexsi save help compani exceed lrp ebit object
nexsi unabl gain materi price benefit nexsi unabl
creat materi valu custom and/or unabl obtain
competit price plasma growth remain line market growth rate
minim cost save drop
stori tie long-
rang plan lrp doubl oper incom
quadrupl turnaround
primarili lever nexsi product
compani next-gener plasma
valu creation materi yield
opportun appreci see
posit backdrop nexsi drive
valu per liter plasma
custom expect share
profit increment per
liter price indic nexsi alon
drive lrp object
complex reduct initi
seek provid cost save
add option de-risk
lrp believ allow haemonet
exceed lrp object
nexsi valu price potenti
drop-through
drop-through
risk achiev price
save program fail materi
lack near-term larg custom contract
nexsi
million except ep
sale
sale
sale
sale
sale
sale
good sold
equival
accum comprehens incom
loss asset dispos
chang work capit
net provid oper activ
capit intang asset
sale properti invest
net use invest activ
chang equiti
net financ activ
net chang
equival bop
equival eop
